Invasive pneumococci before the introduction of pneumococcal conjugate vaccine in Turkey: antimicrobial susceptibility, serotype distribution, and molecular identification of macrolide resistance

References

• Isaacman D, McIntosh ED, Reinert RR. Burden of invasive pneumococcal disease and serotype distribution among Streptococcus pneumoniae isolates in young children in Europe: impact of the 7-valent pneumococcal vaccine and considerations for future conjugate vaccines. Int J Infect Dis. 2010;14:197–209.
   PubMed Web of Science ®Google Scholar
• Hsu HE, Shutt KA, Moore MR, Beall BW, Bennett NM, Craig AS, et al. Effect of pneumococcal conjugate vaccine on pneumococcal meningitis. N Engl J Med. 2009;360:244–56.
   PubMed Web of Science ®Google Scholar
• Appelbaum PC. Antimicrobial resistance in Streptococcus pneumoniae: an overview. Clin Infect Dis. 1992;15:77–83.
   PubMed Web of Science ®Google Scholar
• Linares J, Ardanuy, Pallares R, Fenoll A. Changes in antimicrobial resistance, serotypes and genotypes in Streptococcus pneumoniae over a 30-year period. Clin Microbiol Infect. 2010;16:402–10.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Worldwide progress in introduction of pneumococcal conjugate vaccine, 2000–2008. WHO Wkly Epidemiol Rep. 2008;83:385–92.
   PubMedGoogle Scholar
• Ministry of Health of Turkey General Directorate of Primary Health Care Services. Notice for expanded immunization program, 2009/17. http://www.saglik.gov.tr/TR/belge/1-8187/genisletilmis-bagisiklama-programi genelgesi2009.html (accessed 2009 March 13).
   Google Scholar
• Yalçın I, Gürler N, Alhan E, Yaman A, Turgut M, Çelik Ü, et al. Serotype distribution and antibiotic susceptibility of invasive Streptococcus pneumoniae diseases isolates from children in Turkey, 2001–2004. Eur J Pediatr. 2006;165:654–7.
   PubMed Web of Science ®Google Scholar
• Clinical Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing. Twenty-second informational supplement, M100-S22. Wayne, PA; Clinical and Laboratory Standards Institute; 2012.
   Google Scholar
• Koneman EW, Allen SD, Janda WM, Schreckenberger PC, Winn WC. Color atlas and textbook of diagnostic microbiology, 5th edn. Philadelphia; Lippincott-Raven Publishers; 1997. p. 577.
   Google Scholar
• Leclercq R. Mechanisms of resistance to macrolides and lincosamides: nature of the resistance elements and their clinical implications. Clin Infect Dis. 2002;34:482–92.
   PubMed Web of Science ®Google Scholar
• Sener B, Köseoglu O, Gür D, Bryskier A. Mechanisms of macrolide resistance in clinical pneumococcal isolates in a university hospital, Ankara, Turkey. J Chemother. 2005;17:31–5.
   PubMed Web of Science ®Google Scholar
• Gülay Z, Özbek OA, Biçmen M, Gür D. Macrolide resistance determinants in erythromycin-resistant Streptococcus pneumoniae in Turkey. Jpn J Infect Dis. 2008;61:490–3.
   PubMed Web of Science ®Google Scholar
• Slotved HC, Kaltoft M, Skovsted IC, Kerrn MB, Espersen F. Simple, rapid latex agglutination test for serotyping of pneumococci (Pneumotest-Latex). J Clin Microbiol. 2004;42:2518–22.
   PubMed Web of Science ®Google Scholar
• Sutcliffe J, Grebe T, Tait-Kamradt A, Wondrack L. Detection of erythromycin-resistant determinants by PCR. Antimicrob Agents Chemother. 1996;40:2562–6.
   PubMed Web of Science ®Google Scholar
• Widdowson C, Klugman KP. Emergence of the M-phenotype of erythromycin-resistant pneumococci in South Africa. Emerg Infect Dis. 1998;4:277–81.
   PubMed Web of Science ®Google Scholar
• Cooper D, Yu X, Sidhu M, Nahm MH, Fernsten P, Jansen KU. The 13-valent pneumococcal conjugate vaccine (PCV13) elicits cross-functional opsonophagocytic killing responses in humans to Streptococcus pneumoniae serotypes 6C and 7A. Vaccine. 2011;29:7207–11.
   PubMed Web of Science ®Google Scholar
• Braconier JH, Myhre EB, Odeberg H. Cross-reacting opsonic antibodies to clinically important pneumococcal serotypes after pneumococcal vaccination. Eur J Clin Microbiol. 1983;2:453–8.
   PubMedGoogle Scholar
• Weil-Olivier C, van der Linden M, de Schutter I, Dagan R, Mantovani L. Prevention of pneumococcal diseases in the post-seven valent vaccine era: a European perspective. BMC Infect Dis. 2012;12:207.
   PubMed Web of Science ®Google Scholar
• Song JH, Dagan R, Klugman KP, Fritzell B. The relationship between pneumococcal serotypes and antibiotic resistance. Vaccine. 2012;30:2728–37.
   PubMed Web of Science ®Google Scholar
• Kaltoft MS, Zeuthen N, Konradsen HB. Epidemiology of invasive pneumococcal infections in children aged 0–6 years in Denmark: a 19-year nationwide surveillance study. Acta Pediatr Suppl. 2000;89:3–10.
   PubMedGoogle Scholar
• Jetté LP, Delage G, Ringuette L, Allard R, De Wals P, Lamothe F, et al. Surveillance of invasive Streptococcus pneumoniae infection in the province of Quebec, Canada, from 1996 to 1998: serotype distribution, antimicrobial susceptibility, and clinical characteristics. J Clin Microbiol. 2001;39:733–7.
   PubMed Web of Science ®Google Scholar
• Diez-Domingo J, Pereino I, Morant A, Gimeno C, Lerma M, Oyagüez I, et al. Epidemiology of invasive Streptococcus pneumoniae infections in children in Spain, 1996-1998. J Infect. 2002;45:139–43.
   PubMed Web of Science ®Google Scholar
• Elmdaghri N, Benbachir M, Belabbes H, Zaki B, Benzaid H. Changing epidemiology of pediatric Streptococcus pneumoniae isolates before vaccine introduction in Casablanca (Morocco). Vaccine. 2012;30:G46–50.
   Google Scholar
• Percin D, Altintop YA, Sumerkan B. Ten year surveillance of invasive Streptococcus pneumonia isolates in central Turkey prior to the introduction of a conjugate vaccine. J Infect Dev Ctries. 2010;4:560–5.
   PubMed Web of Science ®Google Scholar
• Nuorti P, Whitney CG. Prevention of pneumococcal disease among infants and children, use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine. MMWR. 2010;59:1–18.
   PubMedGoogle Scholar
• Klugman KP. Pneumococcal resistance to antibiotics. Clin Microbiol Rev. 1990;3:171–96.
   PubMed Web of Science ®Google Scholar
• Klugman KP, McGee L. Resurgence of the multiresistant pneumococcus in the United States: a commentary. Ped Infect Dis J. 2007;26:473–4.
   PubMed Web of Science ®Google Scholar
• Tomasz A. Antibiotic resistance in Streptococcus pneumoniae. Clin Infect Dis. 1997;24:85–8.
   PubMedGoogle Scholar
• Nagai K, Appelbaum PC, Davies TA, Kelly LM, Hoellman DB, Andrasevic AT, et al. Susceptibilities to telithromycin and six other agents and prevalence of macrolide resistance due to L4 ribosomal protein mutation among 992 pneumococci from 10 central and eastern European countries. Antimicrob Agents Chemother. 2002;46:371–7.
   PubMed Web of Science ®Google Scholar
• Borg MA, Tiemersma E, Scicluna E, van de Sande-Bruinsma N, de Kraker M, Monen J, et al. Prevalence of PEN and erythromycin resistance among invasive Streptococcus pneumoniae isolates reported by laboratories in the southern and eastern Mediterranean region. Clin Microbiol Infect. 2009;15:232–7.
   PubMed Web of Science ®Google Scholar
• Erdem H, Pahsa A. Antibiotic resistance in pathogenic Streptococcus pneumoniae isolates in Turkey. J Chemother. 2005;17:25–30.
   PubMed Web of Science ®Google Scholar
• Erdem H. An update on invasive pneumococcal antibiotic resistance in Turkey, 2008. J Chemother. 2008;20:697–701.
   PubMed Web of Science ®Google Scholar
• Felmingham D, Canton R, Jenkins SG. Regional trends in beta-lactam, macrolide, fluoroquinolone and telithromycin resistance among Streptococcus pneumoniae isolates 2001–2004. J Infect. 2007;55:111–8.
   PubMed Web of Science ®Google Scholar
• Halpern MT, Schmier JK, Snyder LM, Asche C, Sarocco PW, Lavin B, et al. Meta-analysis of bacterial resistance to macrolides. J Antimicrob Chemother. 2005;55:748–57.
   PubMed Web of Science ®Google Scholar
• European Antimicrobial Resistance Surveillance System in Europe. EARSS. Annual Report 2011. Available from: http://www.ecdc.europa.eu/en/publications/publications/antimicrobial-resistance-surveillance-europe-2011.pdf
   Google Scholar
• Sener B, Tunçkanat F, Ulusoy S, Tunger A, Soyletir G, Mulazımoğlu L, et al. A survey of antibiotic resistance in Streptococcus pneumoniae and Haemophilus influenzae in Turkey, 2004 2005. J Antimicrob Chemother. 2007;60:587–93.
   PubMed Web of Science ®Google Scholar
• European Antimicrobial Resistance Surveillance System in Europe. EARSS. Annual Report 2008. Available from: http://www.ecdc.europa.eu/en/activities/surveillance/ears-net/documents/2008_earss_annual_report.pdf
   Google Scholar
• Fenoll A, Granizo JJ, Agular L, Gimenez MJ, Aragoneses-Fenoll L, Hanquet G, et al. Temporal trends of invasive Streptococcus pneumoniae serotypes and antimicrobial resistance patterns in Spain from 1979 to 2007. J Clin Microbiol. 2009;47:1012–20.
   PubMed Web of Science ®Google Scholar
• Munoz R, De La Campa AG. ParC subunit of DNA topoisomerase IV of Streptococcus pneumoniae is a primary target of fluoroquinolones and cooperates with DNA gyrase A subunit in forming resistance phenotype. Antimicrob Agents Chemother. 1996;40:2252–7.
   PubMed Web of Science ®Google Scholar